Auna S.A. Reports Q2 2026 Financial and Operational Results
Latin American healthcare provider Auna S.A. released its financial results for the second quarter of 2026, highlighting a period of robust top-line growth, operational pivots, and key capital adjustments across its primary operating regions: Mexico, Colombia, and Peru. Despite facing localized macroeconomic headwinds and temporary margin compression, the healthcare system continues to push forward with strategic expansions and disciplined working capital initiatives.
Strategic Performance and Operational Drivers
Auna achieved a consolidated revenue growth of 9% year-over-year. This top-line expansion was principally catalyzed by a deliberate strategic realignment toward high-complexity medical services. Most notably, the company experienced a 20% sequential surge in specialized oncology treatments within Mexico. This volume recovery was further supported by securing upgraded tier classifications with leading private insurers, restoring momentum after operational restructuring executed over the past year.
However, Adjusted EBITDA contracted by 9% during the quarter. Management attributed this temporary profitability squeeze to targeted investments in elite medical leadership across Mexican operations, combined with one-off billing reconciliation penalties in Peru. In Colombia, Auna successfully shifted its payer portfolio toward risk-sharing agreements, which now account for 24% of regional revenue compared to 14% in the previous year. This strategic adjustment enhances long-term cash predictability and reduces credit exposure.
In Peru, membership grew by 6%, bolstered by a major enterprise B2B agreement covering 7,000 corporate employees. Despite onboarding costs dampening immediate profitability, long-term customer lifetime value remains strong. Furthermore, free cash flow skyrocketed by 181%, reflecting aggressive working capital management, optimized collections in Colombia, and extended supply chain financing structures.
Outlook and Strategic Initiatives
Looking ahead, Auna’s executive leadership reaffirmed its full-year 2026 revenue guidance of approximately 12% foreign-exchange (FX) neutral growth. Adjusted EBITDA growth is targeted toward the lower bound of the 10% to 14% range, excluding non-recurring Peruvian billing adjustments. Operating cash flow generation and margin recovery in the second half of 2026 are expected to pull the company’s net debt to EBITDA leverage ratio below the target threshold of 3x by year-end.
- Lima Sur Expansion: Construction of an asset-light clinical facility in Lima Sur remains underway, scheduled to open between late 2027 and early 2028.
- Colombian Margin Recovery: Implemented contractual price increases will take full effect during H2 2026 to counter mandatory statutory wage hikes and talent retention costs.
- CapEx Allocation: Selective growth capital investments have resumed in Colombia, including additional Intensive Care Unit (ICU) bed capacity in Monteria.
Non-Recurring Impacts and Risk Factors
Quarterly performance absorbed several non-recurring operational impacts. In Peru, retroactive receivables reconciliation penalties weighed on quarterly EBITDA, though management anticipates resolving all legacy payer negotiations before the conclusion of fiscal year 2026. In Mexico, revenue growth was impacted by the calendar timing of Easter holidays and the rollout of a new value-added tax (VAT) on private insurance premiums. On the treasury front, foreign exchange gains fell by PEN 61 million year-over-year following a comprehensive reset of the company’s FX hedging portfolio executed at the end of 2025 to mitigate macroeconomic volatility.
Frequently Asked Questions (FAQ)
What primary factors drove Auna’s revenue growth in Q2 2026?
Revenue growth of 9% was driven primarily by high-complexity care demands, highlighted by a 20% sequential rise in oncology procedures in Mexico, alongside a 6% increase in Peruvian membership contracts and favorable insurer tier reclassifications.
Why did Auna’s Adjusted EBITDA decrease despite higher revenue?
Adjusted EBITDA fell by 9% due to upfront investments in senior medical talent in Mexico and one-time legacy billing reconciliation penalties accepted from payers in Peru.
What is Auna’s financial leverage target for the end of 2026?
Auna aims to bring its net debt to EBITDA ratio below 3x by the end of fiscal year 2026, supported by accelerating cash generation and sequential EBITDA recovery in the second half of the year.
